Evidence of Lung Function for Stratification of Cardiovascular Disease Risk

Hwa Mu Lee, MD,1,2 Steven T. Truong, BS,1 and Nathan D. Wong, PhD1

1Heart Disease Prevention Program, Divisions of Cardiology, Department of Medicine, University of California, Irvine, CA, USA

ABSTRACT

Among adults in the United States, the prevalence of reduced lung function including obstructive and restrictive lung disease is about 20%, representing an over 40 million adults. Persons with reduced lung function often demonstrate chronic systemic inflammation, such as from elevated levels of C-reactive protein. Substantial data suggests that inflammation may have a significant role in the association between reduced lung function and cardiovascular disease (CVD); however, how reduced lung function predicts CVD as risk modification remains largely unknown. Poor lung function has been shown to be a better predictor of all-cause and cardiac-specific mortality than established risk factors such as serum cholesterol, and CVD is the leading cause of mortality among those with impaired lung function. The exact mechanism of atherosclerosis is not clear, but persistent low grade inflammation is considered as one of the culprits in clot formation. The initial presentation of coronary heart disease is either myocardial infarction or sudden death in approximately half of the individuals. Unfortunately, conventional risk factor assessment predicts only 65-80% of future cardiovascular events, leaving many middle-aged and older individuals to manifest a major cardiovascular event despite being classified low risk by the Framingham risk estimates. (Korean Circ J 2011;41:171-174)

KEY WORD: Respiratory function test.

Introduction

In spite of a current evidence-based approaches to cardiovascular disease (CVD) reduction, coronary heart disease (CHD) remains the leading cause of mortality in the industrialized world. Preventive strategies utilize risk assessment to identify those most likely to benefit from medical interventions to reduce risk for CVD events.11 The Framingham Risk Score (FRS) is a global risk algorithm using multiple risk factors such as age, sex, smoking history, systolic blood pressure (BP), total cholesterol, and high density lipoprotein-cholesterol (HDL-C) to estimate 10-year CHD event risk in individuals not previously diagnosed with heart disease.12 While FRS is widely used as a risk assessment tool, it is not entirely reliable in its ability to differentiate individuals regarding CVD events.13 A subject of interest is whether various novel risk markers such as C-reactive protein (CRP)14 or screening tests such as coronary calcium scanning15 can further add to the prediction of CVD events over global risk. Furthermore reduced lung function has been described as risk factor, but remains unsettled.

Cardiovascular Disease and Inflammation

Clinical evidence accumulated since 1990 has established inflammatory processes as important contributors to atherosclerosis, as well as to the vulnerability of an atherosclerotic lesion to rupture or erosion.16 Based on this evidence, protein markers of inflammation have been studied as noninvasive indicators of underlying atherosclerosis in apparently healthy individuals and of the risk of recurrent events in patients with established atherosclerotic vascular disease. The most exten-
sively studied biomarker of inflammation in CVD is CRP, for which standardized high-sensitivity assays are widely available and since hs-CRP has also been shown to be an independent predictor of atherosclerosis among apparently healthy men and women and also improves prediction of CVD risk over traditional risk factors, measurement of hs-CRP has been proposed for use in asymptomatic intermediate risk individuals for further risk stratification. Although it is plausible that serum CRP is a nonspecific marker that is increased as part of the acute phase response to inflammation, experimental evidence has raised the possibility that CRP is a direct participant in the progression of atherosclerosis and its clinical consequences.

**Lung Function and Cardiovascular Disease**

Previous epidemiologic studies have shown reduced pulmonary function to be a significant predictor of CVD including CVD mortality. There is also abundant literature describing a significant relationship between lung function and all-cause mortality. Most of these studies included smokers in their samples and used forced expiratory volume in one second (FEV1) as a measure of lung function. Smoking status was shown to be causally related to mortality. However, the link between poor lung function and mortality has also been reported in never-smokers.

Poor lung function has been shown to be a better predictor of all-cause and cardiac mortality than established risk factors such as serum cholesterol. The cause of this relationship remains largely unknown, but low grade inflammation was present in participants with moderate and severe airflow obstruction and was also associated with increased risk of cardiac injury and this may in part explain the high rates of cardiovascular complications in chronic obstructive pulmonary disease (COPD). There have been recommendations for the use of subclinical disease screening measures in intermediate risk individuals, such as with coronary calcium scanning to be incorporated into risk stratification algorithms to refine the intensity of clinical management of key risk factors.

Individuals in this risk group are often quite heterogeneous and with treatment guidelines that are not always clear. A recent study shows the potential importance of pulmonary function assessment in risk stratification for mortality, particularly for those individuals classified into the intermediate FRS group.

**Lung Function and Inflammation**

Reduced lung function, as assessed by peak expiratory flow, forced vital capacity (FVC) in 1 second (FEV1) and FVC, is associated with a increase in the occurrence of vascular alterations and cardiovascular morbidity and mortality in both smokers and non-smokers.

Recent reports showing the relation between inflammatory markers of either fibrinogen or CRP to reduced lung function in cross-sectional and prospective studies make inflammation a possible mechanism. An increase in serum CRP over time are associated with a significant decline of lung function, consistent with hypothesis that low-grade systemic inflammation is associated with lung function impairment in young adults.

In a large elderly cohort, baseline fibrinogen levels were inversely related to FEV1 and FEV1/FVC ratio, and baseline CRP levels were inversely associated with FEV1 and FVC. Elevated fibrinogen level predicted greater longitudinal declines in FEV1/FVC with increasing age, and a similar, but nonsignificant association was found with CRP.

Individuals with COPD are at increased risk of CVDs, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A systematic review was conducted of studies which reported on the relationship between COPD, FEV1 or FVC, and levels of various systemic inflammatory markers: CRP, fibrinogen, leucocytes, tumor necrosis factor-α, and interleukins 6 and 8 and concluded that most of inflammatory markers are associated with reduced lung function.

Reduced lung function with COPD and restrictive lung disease also is associated with increasing inflammatory markers such as a CRP and fibrinogen. However, the relation between reduced lung function with restrictive lung disease and CVD has not been well established, whereas COPD has been well demonstrated as risk factor for CVD. COPD is being considered as systemic inflammatory disease not limited pulmonary system and statins have been shown to have pleiotropic anti-inflammatory and immune modulatory effects in addition to their cholesterol lowering ability.

Three large prospective observational studies reported that patients with COPD on a statin had substantial reduction in both morbidity and mortality compared with those with COPD who were not. In a reported non-randomized study of lung function screening with COPD, compared with those not on statins, those taking statins had a significantly reduced annual FEV1 decline and reduction in COPD related hospitalization.

The current collective evidence suggests that statins have a positive impact on outcomes of COPD patients. Despite the encouraging results, all studies reported to date have limitations and should be considered as hypothesis generating only.

There are four randomized, double blinded, placebo-controlled design, clinical trials addressing the effect of statins in the US National Institute of Health trials registry as of 1 January 2009.
Conclusion

Traditional global risk assessment for CVD is limited by the ability to differentiate CVD events. Reduced lung function has been described as predictor of CVD and mortality. Systemic low grade inflammation has been considered as a significant player in this association.

There have been recommendations for the use of subclinical disease screening measures in intermediate-risk individuals, such as those with coronary calcium scanning, to be incorporated into risk stratification algorithm to refine the intensity of clinical management for key risk factors. A recent study shows the potential importance of lung function measurement in risk stratification for mortality, particularly for those in the intermediate FRS group. Lung function measures provide additive prediction for all-cause mortality when combined with traditional risk assessment using FRS, particularly in individuals at intermediate risk group.

The clinical implications of lung function measurement include their use in assessing risk in individuals who are at intermediate cardiovascular risk for targeting who may best benefit from therapy.

REFERENCES

1) Gluckman TJ, Baranowski B, Ashen MD, et al. A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med 2004;164:1490-500.
2) D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
3) Thompson JB, Rivera JJ, Blumenthal RS, Danyi P. Primary prevention for patients with intermediate Framingham risk scores. Curr Cardiol Rep 2006;8:261-6.
4) Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990;65:168-72.
5) Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
6) Wilson PW, Smith SC Jr, Blumenthal RS, Burke GL, Wong ND. 34th Bethesda conference task force #4: how do we select patients for atherosclerosis imaging? J Am Coll Cardiol 2003;41:1898-906.
7) Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA writing committee to update the 2000 expert consensus document on electron beam computed tomography) developed in collaboration with the society of atherosclerosis imaging and prevention and the society of cardiovascular computed tomography. J Am Coll Cardiol 2007;49:378-402.
8) Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R Sr, O’Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7.
9) Greenland P, Alpert JS, Bella GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol 2010;56:e50-103. doi: 10.1016/j.jacc.2010.09.001.
10) Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
11) Nilsson J. CRP: marker or marker of cardiovascular disease? Arterio-
12) Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128-34; discussion 2151.
13) Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. Am Heart J 1983;105:311-5.
14) Marcus EB, Curb JD, MacLean CJ, Reed DM, Yano K. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol 1989;129:97-104.
15) Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106:2555-60.
16) Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003:158:1171-81.
17) Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-9.
18) Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970;21:418-24.
19) Beatty TH, Newill CA, Cohen BH, Tockman MS, Bryant SH, Spurgeon HA. Effects of pulmonary function on mortality. J Chronic Dis 1985;38:703-10.
20) Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington county, Maryland. Am Rev Respir Dis 1989;140:S56-63.
21) Hole DJ, Watt GC, Darvey-Smith G, Hart CL, Gilliss CR, Hawthorne VM. Impaired lung function and mortality risks in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-5.
22) Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-64.
23) Curb JD, Marcus EB, Reed DM, MacLean C, Yano K. Smoking, pulmonary function and mortality. Ann Epidemiol 1996;1:25-32.
24) Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality in never smokers. J Clin Epidemiol 1990;43:867-73.
25) Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
26) Lee HM, Le H, Lee BT, Lopez VA, Wong ND. Forced vital capacity paired with Framingham risk score for prediction of all-cause mortality. Eur Respir J 2010;36:1002-6.
27) Jiang R, Burke GL, Enright PL, et al. Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol 2008;168:602-10.
28) Thyagarajan B, Jacobs DR, Apostol GG, Smith LJ, Lewis CE, Williams OD. Plasma fibrinogen and lung function: the CARDIA Study. Int J Epidemiol 2006;35:1001-8.
29) Hancock RJ, Poulton R, Greene JM, et al. Systemic inflammation and lung function in young adults. Thorax 2007;62:1064-8.
30) Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med 2006;100:2112-20.
31) Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007;62:515-20.
32) Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive protein with reduced forced vital capacity in a nonsmoking U. S. population with metabolic syndrome and diabetes. Diabetes Care 2008;31:2000-2.
33) Gan WQ, Man SF, Senthilsevan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a
systematic review and a meta-analysis. Thorax 2004;59:574-80.

34) Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination. Am J Med 2003;114:758-62.

35) Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60.

36) Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83.

37) Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.

38) Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kina-sewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71.

39) Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61:472-7.

40) Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006;173:985-90.

41) Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systemic review. Chest 2009;136:734-43.